• AZMCF expanding the 100%-owned Kay Mine Projects in Arizona, surrounded by sixty historic underground VMS copper, gold, zinc, and silver mines
• Volcanogenic massive sulfide (“VMS”) deposits are critical global sources of copper, zinc, lead, gold, and silver ores
• Recent company update reveals progress on Kay Mine Project, including 33,000 meters of core drilling completed in 2022, drill permits received for Central and Western targets, and drilling initiated on targets outside deposit
• Company fully funded (cash of $58 million at Sept 30, 2022) to complete remaining 8,600 meters for Kay Mine Phase 2, as well as 76,000 meters for Phase 3

Arizona Metals (TSX: AMC) (OTCQX: AZMCF), a mineral exploration company, recently provided a year-end review and updates on its 100%-owned Kay Mine VMS Project and Sugarloaf Peak Gold Project in Arizona (https://ibn.fm/Uvy2n). During 2022, the company completed approximately 33,000 meters of core drilling at the Kay Mine Deposit, received drill permits for both the Central and Western Targets, and initiated drilling on targets outside the deposit.

As of September 2022, AZMCF was fully funded to complete the remaining 8,600 meters planned for the Kay Mine Phase 2 program, and an additional 76,000 meters for Phase 3. Both programs will test numerous parallel targets west of the Kay Mine Deposit, along with possible northern and southern extensions.

“As we begin 2023, I want to take a moment to reflect on the past year and share some of our accomplishments,” said AZMCF CEO Marc Pais. “First, I want to thank our shareholders for your continued support and belief in Arizona Metals. Your trust and investment have been a driving force in creating one of the best-financed explorers listed on the TSX and advancing what we believe to be one of the world’s premier VMS exploration projects.”

Volcanogenic massive sulfide (“VMS”) deposits represent a critical global source of copper, zinc, lead, gold, and silver ores. AZMCF aims to tap into the potential of Arizona’s Yavapai County with its 100%-owned projects surrounded by sixty historic underground VMS copper, gold, zinc, and silver mines.

VMS ore deposits are typically associated with and created by volcanic-associated hydrothermal events in submarine environments (https://ibn.fm/uvwM4). They are predominantly copper-zinc metal sulfide ore deposits occurring in areas dominated by volcanic or volcanic-derived rocks. Currently, VMS deposits are formed around volcanoes under the sea and along many ridges in the middle of the ocean within forearc rifts and back-arc basins. While some mineral exploration firms explore on the sea floor, most companies focus on land-based equivalents.

Yavapai County, located in mining-friendly Arizona, is a prolific mining district with substantial historic resources, one of which AZMCF is currently exploring, developing, and expanding. The company’s fully owned flagship Kay Mine property totals 1,300 acres that are not subject to any royalties. A historic 1982 estimate by Exxon Minerals revealed a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver” (https://ibn.fm/C2zjb). (1)

According to a report by Westworld Resources in 1983, AZMCF’s fully owned Sugarloaf Peak Property in La Paz County has a historical estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. (2)

Based in Toronto, Canada, Arizona Metals advances precious and base metal deposits in Arizona. The company’s management team leverages decades of geological engineering, precious metals exploration, and investment banking experience to develop world-class VMS exploration projects.

(1) The historic estimate at the Kay Mine Deposit was reported by Exxon Minerals in 1982. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

(2) The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

For more information, visit the company’s website at www.ArizonaMetalsCorp.com.

Full Disclosure: Arizona Metals Corp. is an InvestorBrandNetwork marketing client.

NOTE TO INVESTORS: The latest news and updates relating to AZMCF are available in the company’s newsroom at https://ibn.fm/AZMCF

• Every country in the world signed the Paris agreement at COP 21 in 2015, 50+ countries have committed to Net-Zero by 2050
• GeoSolar helps ease energy transition with the SmartGreen(TM) whole-home renewable energy system
• GeoSolar’s SmartGreen(TM) system offers a total-home makeover, including geothermal-powered heat pump, solar panels, upgrades to insulation, windows, lighting systems

Every country in the world signed the Paris agreement at COP 21 in 2015 with the shared aim of limiting global temperature increases as close as possible to 1.5 degrees Celsius (https://ibn.fm/iDbjH). Since then, over 50 countries have committed to adopting a net-zero emissions goal by 2050 – including the United States (https://ibn.fm/kqTZ5). GeoSolar Technologies (“GST”), a Colorado-based climate technology company, helps ease the transition with the SmartGreen(TM) Home system for newly built and existing residences and commercial buildings.

Individual states throughout the US are also taking measures to promote renewable energy and reduce carbon emissions. GeoSolar’s home state of Colorado is among those taking bold steps to achieve Net-Zero through a proposed bill that uses 2005 benchmark levels to set greenhouse gas reduction goals of 65% by 2035, 80% by 2040, 90% by 2045, and 100% in 2050 (https://ibn.fm/skbhP). Other states are also taking action to reduce emissions, including Washington State, California, Illinois, New York, and New Jersey (https://ibn.fm/ONa4j).

GeoSolar’s SmartGreen(TM) whole home energy system helps building owners achieve energy independence while eliminating carbon emissions. Geothermal ground loops, air ducts, and photovoltaic solar panels tap into the energy of the earth and sun to power electric appliances and vehicles. In addition, the SmartGreen(TM) system improves efficiency throughout the entire home by tightening the building envelope and upgrading insulation, windows, and lighting systems.

SmartGreen(TM) is suitable for warm and cold climates and can be retrofitted to existing buildings or integrated into new construction. Besides offering energy independence, the SmartGreen(TM) system can also drastically reduce or eliminate utility bills and increase the building’s value.

GeoSolar aims to market SmartGreen(TM) to over 120 million homes across the United States with 100% financing options, valuable tax deductions, and utility incentives. The company is also giving the public an opportunity to own a piece of GeoSolar Technologies Inc. and the SmartGreen system through a Reg A+ capital raise that enables anyone to become a shareholder.

For more information on GeoSolar’s Regulation A+ capital raise, please visit https://www.manhattanstreetcapital.com/geosolar-technologies-inc.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Lexaria Bioscience recently released its 2023 annual letter from CEO Chris Bunka, providing a strategic update to all stakeholders
• The letter highlights the key milestones achieved in calendar 2022, outlines expectations for calendar 2023, and indicates why Chris Bunka expects 2023 to be the company’s best year so far
• 1In calendar 2023, Lexaria expects to attain FDA registration for an investigational new drug (“IND”) program and commence Phase 1(b) clinical study evaluating the safety and tolerability of DehydraTECH(TM)-processed CBD as a treatment for hypertension
• The company will also be pursuing commercial relationships in 2023 even as its R&D continues to progress by engaging in discussions with potential collaborators who may license the patented DehydraTECH technology

Lexaria Bioscience (NASDAQ: LEXX) started calendar 2022 with optimism, which according to CEO Chris Bunka’s recently published annual letter to shareholders (https://ibn.fm/zu8hP), turned out to well founded. Now, as the company begins calendar 2023, “that optimism is, if anything, even stronger today.” Lexaria has reason to be optimistic about the current year, coming off a year that saw it successfully fulfill its primary objectives and tick most, if not all, of the boxes on its priority list.

At the start of calendar 2022, the company intended to introduce its patented DehydraTECH(TM) drug delivery technology to world-leading collaborators and to avoid raising additional funds through the capital markets. It also planned to develop its DehydraTECH-CBD hypertension program, explore whether DehydraTECH-nicotine pouches could replace nicotine administration via inhalation (smoking), and evaluate DehydraTECH-CBD as a therapeutic against other conditions such as epilepsy, dementia, and diabetes. Lexaria, through Chris Bunka’s letter, is pleased to report that these objectives were wholly completed in 2022 or are nearing completion in early 2023.

The completed objectives include the introduction of DehydraTECH to potential licensees via ongoing discussions as well as the completion of EPIL-A21-1 animal study evaluating DehydraTECH-CBD as an anti-seizure therapeutic and the HYPER-H21-4 human clinical study evaluating DehydraTECH-CBD as a potential treatment for hypertension.

The results affiliated with the primary objectives of the HYPER-H21-4 study, namely the blood pressure and pharmacokinetic performance, were positive, with no serious adverse events observed. It is, therefore, accurate to say that the study was a success, Bunka writes. Moreover, in the EPIL-A21-1 study, DehydraTECH-CBD demonstrated certain performance enhancements, namely more efficacy at lower doses and more rapid action, than Epidiolex, a leading CBD-based anti-seizure medication. Of note, and following the success of the EPIL-A21-1 seizure study, Bunka writes, Lexaria is rating its DehydraTECH-CBD for seizure investigation as one of its highest priorities along with the DehydraTECH-CBD for hypertension and DehydraTECH-nicotine.

In the Q1 of calendar 2023, the company expects to complete dosing in the human nicotine study NIC-H21-1, the animal diabetes study, and the animal dementia study, having initiated them in late 2022. The company is also evaluating a series of secondary objectives of HYPER-H21 4 study, with some of the findings and additional results expected within this period.

Remarkably, the company achieved these milestones and managed the growth while exercising excellent fiscal controls. In fact, and despite the inflationary pressures, Lexaria hit its annual 2022 budget, +/- about 2%, building on an accomplishment that began in 2021. This helped the company preserve its existing capital and stay true to its earlier commitment not to raise additional funds by issuing equity or taking on any debt. As a result, its cash in hand is enough to support operations through nearly all of 2023 without needing to raise additional capital if the company chooses to reduce its R&D spending.

“However, as we prefer to keep advancing our applied R&D at as rapid a pace as we can, we are also continuing to pursue capital-strengthening possibilities that do not involve the issuance of any equity,” Bunka writes.

According to the letter, the R&D programs and the capital-strengthening opportunities are interlinked. If successful, the DehydraTECH-CBD hypertension program, for example, is expected to help increase not only Lexaria’s corporate value but also the probability of reaching one or more commercial out-licensing agreements within the pharmaceutical industry. In addition, the success could also pave the way for more commercial pursuits of its DehydraTECH-CBD for therapeutic use. Similarly, if the nicotine study is successful, the company feels it will have inched closer to completing its scientific investigations, positioning it to market the technology to the global nicotine industry in pursuit of growing revenue streams.

“Each of these three areas of investigation [DehydraTECH-CBD as a hypertension therapeutics, DehydraTECH-CBD as an anti-seizure medication, and DehydraTECH-nicotine] has the potential to support important industry relationships that prove meaningful or even transformative for Lexaria. Because of the obvious medical and market needs in each of these three sectors, we will be pursuing commercial relationships in 2023 even as our R&D continues to progress,” the letter reads.

Accordingly, Lexaria’s CEO expects calendar 2023 will be the company’s “best year ever.” Among the key milestones the company intends to achieve is a Food and Drug Administration (“FDA”) registration for an Investigational New Drug (“IND”) program that will sanction the commencement of a Phase 1(b) FDA-registered clinical trial evaluating the safety and tolerability of DehydraTECH-CBD as a treatment for hypertension. The company expects this research program will dominate the second half of calendar 2023 and beyond.

In all, the registered clinical trials for DehydraTECH-CBD are expected to culminate in the filing of a new drug application (“NDA”) via the abbreviated 505(b)(2) pathway. To support this shortened route to commercial approval, Bunka says, Lexaria will leverage precedent safety data generated from the clinical study of FDA-approved Epidiolex. In its trials, for example, Epidiolex demonstrated the pharmaceutical’s safety and tolerability when administered chronically but at much higher doses than Lexaria’s intended dosing of DehydraTECH-CBD.

Still, the company maintains that DehydraTECH-CBD is not its only long-term plan for FDA registration. “Stakeholders can follow our progress in other areas of therapeutic interest through the results we receive in our applied R&D programs,” emphasizes Bunka.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Backcountry aviation innovator CubCrafters is advancing its ability to respond to customers of its popular XCub and other aircraft products by welcoming outside investors
• CubCrafters’ public investment offering was initially introduced last year through a Reg A+ filing qualified by the FTC in November, at which point more than $26 million of its $50 million goal had already been reserved pre-offering
• The company announced Jan. 17 that it has expanded that investment opportunity to residents in Florida, New Jersey, Texas, and Washington, through a Regulation CF campaign serving non-accredited investors who couldn’t qualify under the Reg A+ program
• Both investment offerings offer the same terms — $5 per share and a minimum investment of $400

The introduction of a new Regulation CF campaign by Yakima, Wash.-based aviation company CubCrafters has helped the best-in-class backcountry aircraft producer clear a critical hurdle to accepting investments from non-accredited investors in several states as a result of local restrictions in those states.

The allowance for investment from non-accredited investors living in Florida, New Jersey, Texas and Washington means it is now possible for investors in every state to participate in CubCrafters’ public offering if they wish.

“Our fans, customers, aviation enthusiasts, employees, and even the general public in the states of Florida, New Jersey, Texas, and Washington have told us that they very much want to participate in this investment opportunity,” CubCrafters President and CEO Patrick Horgan stated in the company’s news release (https://ibn.fm/lWwS4). “It was always our intention for everyone to be able to participate in our offering regardless of their location, and now they can.”

CubCrafters unveiled its plans to become a publicly funded company in July with an announcement that it would accept reservations for preferred stock under a Reg A+ filing, and in November Horgan announced the Federal Trade Commission (“FTC”) qualified the Reg A+ filing, opening the door for the investors to come onboard (https://ibn.fm/8OdXy).

The new Regulation CF campaign offers the same terms for preferred stock to the public — an initial price of $5 per share and a minimum investment of $400, according to the company.

The company aims to raise up to $50 million and had already received reservations for more than $26 million of its shares within 90 days of its announcement it would accept outside investment for the first time.

CubCrafters builds popular FAA-certified aircraft, light sport airplanes that meet international air traffic flow management (“ATFM”) standards, experimental aircraft for hands-on builders taking advantage of the company’s assistance program, and kits for those prepared to work on their own.

The purpose of the funding drive is to help the company grow sufficiently that it can reduce customers’ wait times (currently booked out at about two years) while also enabling the company to accelerate the pace of innovation to develop faster, more powerful, technically capable aircraft, to improve customer support, and to boost sales in overseas markets where the company flagship XCub aircraft has received international certifications.

Its XCub and Carbon Cub SS models are advanced versions of the legacy Super Cub using current-day technology — a high-performance fixed-wing craft useful for accessing backcountry areas without the need for paved runways, whether for commercial needs or for personal recreation.

The airplanes have lower operational costs than helicopters, which have also made them attractive to the government, leading to a contract with the U.S. Department of Agriculture announced last month to replace some of its aging Piper PA-18 Super Cubs currently in its fleet.

“Our goal here at CubCrafters is to provide them with such a good platform (an aircraft that is more capable, more cost effective, and safer), that they ultimately replace their entire current fleet of around 40 legacy aircraft with the XCub,” Vice President of Sales and Marketing Brad Damm told Flying magazine (https://ibn.fm/1l223).

For more information, visit the company’s website at www.CubCrafters.com.

NOTE TO INVESTORS: The latest news and updates relating to CubCrafters Inc. are available in the company’s newsroom at https://ibn.fm/CUB

• MetAlert recently announced the planned acquisition of TrakTec LLC, a Florida-based leader in location awareness technology for consumer and business applications
• The acquisition is expected to add several products to MetAlert’s existing suite of products, one of which is an RFID and Bluetooth-enabled tracking technology called SafetyNet(R)
• The SafetyNet Tracking System comprises the SafetyNet Bracelets that patients wear, and a receiver-antenna combo used by police departments and first responders
• The Chelmsford Police Department in Massachusetts recently reported it had successfully located a missing senior citizen with dementia because of its participation in the SafetyNet program
• The department has, over time, established that radio frequency can be superior to GPS at successfully tracking missing persons, especially in challenging conditions such as densely wooded areas, buildings, basements, and shallow water

MetAlert (OTC: MLRT), a pioneer in smart, mobile, and wearable GPS tracking and recovery location-based products and services, is implementing a solid growth strategy that has seen it enter into a Heads of Terms agreement to acquire TrakTec LLC, a Florida-based leader in location awareness technology for consumer and business applications. Announced January 11, the agreement is expected to close on or before March 17 this year upon completing satisfactory due diligence and audits (https://ibn.fm/uzKUZ).

The acquisition is expected to add iGPS products, namely the Wizard GPS Tracking Watch Phone for children and the Phoenix GPS-based smartwatch for seniors, and SafetyNet(R), a radio-frequency identification (“RFID”) and Bluetooth-enabled tracking technology, to MetAlert’s existing suite of mostly GPS-based tracking products. Of the additions, SafetyNet stands out because of radio frequency’s unique advantages over GPS in certain outdoor environments.

TrakTec’s SafetyNet System comprises bracelets designed to be worn on the wrist or ankles at all times and individually emit a unique signal that represents the wearable’s own RFID. It is this RFID that is then fed into a receiver to enable tracking. The receivers are meant to be operated by law enforcement officials as part of the SafetyNet Tracking Systems program, with the police departments receiving handheld and vehicle-mounted antennas that isolate and boost the RF produced by the bracelets. Generally, the SafetyNet Tracking System is intended to help public safety agencies quickly locate patients with such conditions as autism, Alzheimer’s disease, and dementia.

Once an alert goes out that a SafetyNet user is missing, the first responders whose vehicle is equipped with an antennae head to the missing person’s last known location. This antenna, which isolates the incoming signals from the bracelet, allows the responders to track the location of the missing person up to a proximity of about a quarter of a mile, at which point the responders shift to the handheld tracking device that has a directional antenna. This device enables the responders to further isolate the person’s location and eventually find them.

Since its formation in 2010, SafetyNet has been deployed in more than 1,000 rescue cases (https://ibn.fm/9FU2W) and is utilized by police departments across more than 15 US states (https://ibn.fm/cN3Ws). One of these departments, the Chelmsford Police Department in Massachusetts, recently reported successfully locating a missing senior citizen with dementia because of its participation in the SafetyNet program (https://ibn.fm/N2aHK).

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

• SILO recently provided status update on its sponsored clinical trial with UCSF examining psilocybin’s effects on inflammation
• Targeted patient populations from study may provide support for development and use of psilocybin as a therapeutic to treat inflammatory conditions
• Data collection from all study groups expected by April 2023
• SILO additionally evaluating its ketamine formulation through its partnership agreement with Zylö Therapeutics

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company that fuses traditional medicine with psychedelics, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. Research into psychedelics like psilocybin has recently experienced a renaissance, specifically for treating depression, addiction, anxiety, obsessive-compulsive disorder, and inflammatory diseases (https://ibn.fm/vnsO7). Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a therapeutic by evaluating the effects of the compound on patients suffering from inflammatory disorders, including Parkinson’s disease, bipolar disorder, and chronic pain. “The UCSF research team is making progress on the clinical trial,” said Eric Weisblum, Chief Executive Officer of Silo Pharma (https://ibn.fm/h7cAA). “The data gathered from these studies could uncover the role of inflammatory activity on such conditions as Parkinson’s, bipolar disorder, and chronic pain. Utilizing psilocybin in this study in a regimented dosing pattern, we hope to gain significant data both in mechanism of action and potential biomarker for personalization of psilocybin therapy.  The targeted patient populations from the study could provide support for the development and use of psilocybin as a therapeutic coupled with our novel homing peptides and topical technology.” The clinical study comprises preparation therapy, two separate dosing sessions with psilocybin, and integration therapy for the three patient populations afflicted with Parkinson’s disease, bipolar disorder, and chronic pain. Blood samples are collected from each patient at four points: one at baseline before treatment begins, one at 24 hours following both dosing sessions, and one after 30 days during a follow-up session. Data collection from the study is expected to be completed by April 2023 for all three patient populations. In addition to its partnership with UCSF, Silo Pharma is also evaluating its ketamine formulation, designated as SPC-14, through a joint partnership agreement with Columbia University (https://ibn.fm/9OQtD). The company initially entered a sponsored pact with the university in October 2021 and has recently extended the contract to continue research for SPC-14 and SPC-15, a targeted therapeutic for stress-induced anxiety disorders (https://ibn.fm/969lZ). Silo Pharma Inc. is fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, rheumatoid arthritis, and other rare neurological disorders. The company partners with leading institutions such as Columbia University, the University of California San Francisco (“UCSF”), and the University of Maryland, Baltimore (“UMB”) to develop treatments the company believes will transform healthcare and improve patient outcomes. For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• The February 15, 2023 Investor Day virtual event will be hosted by the company’s President and CEO, Brian Haugli, and CFO, Ryan Polk
• Reports have shown an increase in cyberattacks due to the growth in network attack surfaces for in-office and remote workers who rely on cloud environments, mobile devices, software applications, and third-party suppliers to conduct business
• SideChannel’s newest product release, Enclave(TM), is a comprehensive cloud and network solution that enables IT teams to contain breaches faster, reduce network outages, minimize latency, and strengthen overall defensive security

SideChannel (OTCQB: SDCH), a provider of cybersecurity services and technology, develops technologies to make cybersecurity simple and accessible, by matching organizations worldwide with expert virtual Chief Information Security Officers (vCISOs), allowing companies to assess cyber risk and ensure cybersecurity compliance, without jeopardizing financial assets. The company has announced its Investor Day event to be held virtually on February 15, 2023, from 9:00 am to 10:30 am EST (https://ibn.fm/LG5ZY). Investor Day will be hosted by SideChannel’s President and CEO, Brian Haugli, and CFO, Ryan Polk, who will provide updates on the Company’s operations, recent developments, and strategic priorities. SideChannel will accept questions from investors via email before the event, which can be submitted to ir@sidechannel.com. Investors planning to attend SideChannel’s Investor Day event will need to preregister for the event by filling out an online form (https://ibn.fm/YvCR1). SideChannel is committed to creating top-tier cybersecurity programs for small and mid-sized businesses, helping them protect their data and assets, and has created over 50 multi-layered cybersecurity programs for clients. The company lends its talents to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for growing enterprises. Reports have shown that cyberattacks on these types of businesses have increased in recent years due to the exponential growth of network attack surfaces. More remote and in-office workers rely on cloud environments, mobile devices, software applications, and third-party suppliers to conduct business. With this in mind, SideChannel is continually expanding its service offerings, workforce, and customer base – attracting over 20 vCISOs to serve across a vast number of industries, including fintech, biotech, healthcare, manufacturing, legal, defense, and technology services. SideChannel’s recent product offering includes Enclave(TM), a comprehensive cloud and network solution that enables IT teams to contain breaches faster, reduce network outages, minimize latency, and strengthen overall security defense. Enclave creates the foundation for a zero-trust network security model that IT can build upon, segmenting a company’s network to organize personnel and computing devices at the employee level and implement security controls across all network segments. The cybersecurity market is projected to reach $173.5 billion by the end of 2023, with security services anticipated to be the largest segment valued at $91.21 billion. The average spend per employee in the cybersecurity market is projected to reach $8,190 in 2023. The market is expected to grow at a CAGR of 10.9%, resulting in a revenue volume of $262.4 billion by 2027. Compared to global revenue, the United States is expected to account for approximately $69.7 million in 2023 (https://ibn.fm/nsWa0). Enclave was designed and purpose-built to serve the growing security needs of small to mid-sized organizations. This traditionally underserved market is more prone to cyber-attacks but has limited protection due to smaller budgets, inadequate IT security staffing, and a lack of cybersecurity awareness among top executives. SideChannel’s product is affordable and effective – shrinking the attack surface area exposed to cyber intruders and significantly reducing the effort required to operate securely. For more information, visit the company’s website at www.SideChannel.com. NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability
• Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract
• Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through various animal and human clinical studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve bioavailability and how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with the speed of onset, and brain absorption. Lexaria is focusing ongoing research and development efforts on the advancement of product candidates across several key segments, including, nicotine replacement, CBD, cardiovascular drugs, antivirals, epilepsy, human hormones, and PDE5 inhibitors. Bioavailability measures how much of a substance enters the bloodstream, with intravenous administration being the most effective approach to 100% bioavailability for maximum effect. While oral administration is less intrusive and preferred, it presents less efficacy and bioavailability of APIs due to obstacles like gut disorders and stomach acid and liver biotransformation. Although Lexaria is focused on pharmaceutical bioavailability, it’s interesting to note that bioavailability even plays a role in nutrition. While macronutrients (carbs and fat) offer higher levels of bioavailability – micronutrients, commonly sold as supplements (vitamins, minerals, flavonoids, and carotenoids), can be harder for the body to absorb. Studies show that not all the nutrients we eat enter the bloodstream after entering the digestive tract. Some factors that affect bioavailability include where the food is grown or made, when it was harvested, how it was prepared, the foods you eat with it, and highly individualized physiological traits that affect how your body processes that food. With studies showing that around 40% of available drugs are poorly bioavailable (https://ibn.fm/xy86j), the determined factors that affect drug bioavailability include:

• The size of the drug’s molecule
• The type of drug administered
• The amount of food eaten
• The time of day the drug is taken

Understanding the bioavailability of a drug is crucial for clinicians looking for appropriate routes of administration and schedule for drug delivery. Lexaria is investigating its DehydraTECH technology for increased bioavailability of APIs with epilepsy, high blood pressure, dementia, diabetes, and more. The global pharmaceutical drug delivery market is projected to reach $2.21 billion by 2026, growing with a CAGR of 5.9% from a value of $1.66 billion in 2021. Growth is highly attributed to factors including the rising prevalence of chronic diseases, the growing biologics market, increased R&D investments, and technological advancements, which include new product launches (https://ibn.fm/cJq4l). Animal studies have also demonstrated a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery. Since 2016, Lexaria’s technology has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to ten times, reduce the onset time from one to two hours to just minutes, and mask unwanted tastes. The company’s recent study, EPIL-A21-1, demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). The study’s results have demonstrated the performance of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and, in some cases, even surpass the performance of Epidiolex. The findings from the study further support Lexaria’s efforts and clinical trials, which are currently being explored for other indications, including hypertension, dementia, and diabetes. The indications explored by Lexaria are chosen due to their current underserved medical needs, as DehydraTECH helps enhance bioavailability of substances for treatment. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Claude Bejet, a long-time precious metals investor and author of the Swiss Gold Letter, was interviewed on the sidelines of the recent Mines and Money Conference in London
• During his interview, Bejet commented on his optimism in regards to the precious metals complex as well as the considerable value held by junior mining companies
• Eloro Resources possesses a 100% option agreement on the Iska Iska deposit, a major polymetallic epithermal porphyry complex covering over 900 hectares of land
• The company is due to publish their initial assessment of Iska iska’s resource potential by March 2023, a process which Eloro are carrying out with mining consultancy, Micon International

“We’ve been through hell.” That was Claude Bejet’s succinct summary of the precious metals market and gold over the past two years. A Covid-linked downturn in 2020 was subsequently followed by an inflation-driven bear market across financial assets in 2022; although gold has historically been perceived as an inflation hedge, a rapidly appreciating US dollar – which rose by over 12% in 2022, hitting a two-decade high in September – marred what could have heralded a banner year for precious metals. However now and on the sidelines of the Mines & Money London conference, Claude Bejet expressed his belief that the worst could now be over; in an interview with industry newswire Kitco Mining, Bejet expressed his renewed optimism on the precious metals complex and commented on his optimism on the overlooked potential of listed mining companies (https://ibn.fm/WJC4x).

Marc Bristow, the CEO of Barrick Gold Corp, told investors during his keynote speech at the conference that the future of mining no longer lay in the traditional, over-explored jurisdictions of prior years. Rather, the big opportunities over the next decade would come from traditionally overlooked jurisdictions with Bolivia ranking chief amongst these. Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec has epitomised the potential success that could be derived from a focus in less traditional jurisdictions. Between 2020 and 2021, Eloro Resources witnessed its stock price rise by over 2,900% – a remarkable outcome resulting from the company’s world class silver-tin discovery with the near inexhaustible Cerro Rico mining belt (https://ibn.fm/FS9GO).

The mines around the Cerro Rico region have gained a near legendary reputation within precious mining circles, having produced approximately 2.1-3 billion ounces of silver over the past 500 years – making it the single richest source of silver in human history. In fact and between the 16^th and 18^th century, 80% of the world’s silver supply originated from the Cerro Rico region. In early 2020, Eloro Resources sought to capitalize on the region’s potential, optioning the Iska Iska project, a 484 square kilometre undeveloped mining tract within the Potosi region – a mere 180 kilometers south of the prolific Cerro Rico deposit.

Since commencing the inaugural drill program at the Iska Iska site in September 2020, Eloro Resources has drilled over 120 holes and 85,000 meters within the property, however it was their initial discoveries in late 2020 that convinced the company of the site’s relative potential. Between November 2020 and January 2021, the company found that its initial holes – most of which were between 250 and 300 meters in length, were delivering bulk tonnage of 150 silver grams equivalent per ton – a level of silver concentration which has been found to be economically viable in the past.

According to Bejet, the current equity market downturn could make for propitious timing for investors seeking to increase their allocation towards listed miners which may have been otherwise been overlooked by the market, with Eloro Resources chief amongst these. Boasting one of the most potentially significant silver and tin deposits within the Cerro Rico region and having recently looked to expand their addressable deposit size through the acquisition of the adjoining Mina Casiterita and Mina Hoyada properties, Eloro Resources may make for one of Bejet’s best bets yet.

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

World(R) on January 26-29, 2023, unites a community of international enthusiasts devoted to podcasting technology and general communication with the world through the medium of audio and video.

Main stage sponsor SiriusXM will be represented at the 9th Annual Podfest Expo(R) 2023 supporting a community of creators whos’ origin began in 2013 as a meetup of 13 attendees. This year’s expo will be topping 1500+ Podcasters enjoying an immersive experience with over 200 Subject matter experts sharing their best practices

The venue of the event is Renaissance Orlando at SeaWorld(R) – within walking distance of SeaWorld(R) Orlando and the Aquatica water park, International Drive, and Orlando’s most celebrated attractions. Enjoy the spacious hotel accommodations with resort-style amenities, Netflix streaming services and inspiring views of SeaWorld(R), to make the Podfest experience memorable.

The event is curated for new as well as seasoned podcasters. The conference topics are easy to understand and customized as per a daily agenda based on what the attendees want to learn. Podfest has plenty to offer to all categories of podcasters who are willing to learn and share their best practices. The exhibitors will be showcasing the latest technology and services in the podcasting industry.

Hosting Podfests since 2015, this conference unites important speakers on a common platform to engage, discuss, and share valuable content with the worldwide Podfest community. The speakers are dignitaries, influencers, and thought leaders, who have profound knowledge in their niche fields.

Attendees can participate and gain knowledge on industry-crucial conference topics that are available in a fully customizable agenda that attendees can tailor per their interests, including:

• Creation and Launch
• Technology and Innovation
• Audience Growth
• Monetization and Marketing
• YouTube and Video
• Networking and Social

Some of the creators presenting at Podfest Expo(R) 2023 include Sara Dean of The Shameless Mom Academy; Kate Erickson of Kate’s Take; Innovation in Compliance with Tom Fox, Bryan Green of The Commercial Break, and Larry Roberts of Red Hat Media sharing how to use Chat GPT as a creator.

To learn more, please visit www.PodFestExpo.com and https://ibn.fm/U5ZEC.